Back in April, we pondered whether the new judge in the Valsartan MDL would change things for the better. In contrast to the Zantac MDL, which was established a year later and has proceeded on a very similar contamination theory, the first several years of the Valsartan MDL saw a bunch of bad rulings on
Not that long ago (last time we posted), the Sixth Circuit issued an unpublished opinion that affirmed the exclusion of an expert (yay!) but missed the boat on the amendments to Federal Rule of Evidence 702 and its reinforcement of the expert exclusion test (boo!).
Today, we get to tell you about a
Recently, when we have spoken of vaccine litigation, it has mostly been about challenges to public health policies requiring vaccination against COVID-19 for healthcare workers, students at public universities, etc. We have been pleased to report that these challenges have been failing without lingering too long at the trial court level, like here, here